本帖最后由 老马 于 2013-3-13 13:43 编辑 - }, T l ]; Q+ g; u
, p1 o4 P$ S! E0 c5 X* E( e
健择(吉西他滨)+顺铂+阿瓦斯汀 {* R: E7 R# x/ l X9 x! n8 L+ m
Gemzar +Cisplatin + Avastin
2 t- v( V4 E1 Zhttp://annonc.oxfordjournals.org/content/21/9/1804.full! f2 c( v0 ]: O- Q, t: F5 X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, R4 i* e" D: rPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 2 p, q7 z- T- Z8 Y5 E
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. S7 i& b$ ], f1 I' _6 g" l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 900)
/ x/ W: p# _9 k/ z% \# v
华为网盘附件:. g3 @3 s5 U: g+ V8 ~- `
【华为网盘】ava.JPG
2 Q1 E( \/ s3 u7 p( J. { |